Heparin Thromboprophylaxis in Medical-Surgical Critically Ill Patients: A Systematic Review and Meta-Analysis of Randomized Trials*
The DOI matches its Crossref record, with a small difference in title or year; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Venous thromboembolism prevention during critical illness is a widely used quality metric. The objective of this systematic review was to systematically review the efficacy and safety of heparin thromboprophylaxis in medical-surgical patients in the ICU. DATA SOURCES: We searched EMBASE, MEDLINE, the Cochrane Controlled Trials Register, Clinicaltrials.gov, and personal files through May 2012. STUDY SELECTION: Randomized trials in adult medical-surgical ICU patients comparing any heparin (unfractionated heparin or low-molecular-weight heparin) with each other or no anticoagulant prophylaxis, evaluating deep vein thrombosis, pulmonary embolism, major bleeding, or mortality. DATA EXTRACTION: Independently, in duplicate, we abstracted trial characteristics, outcomes, and risk of bias. DATA SYNTHESIS: Seven trials involved 7,226 patients. Any heparin thromboprophylaxis compared with placebo reduced rates of deep vein thrombosis (pooled risk ratio, 0.51 [95% CI, 0.41, 0.63]; p<0.0001; I=77%) and pulmonary embolism (risk ratio, 0.52 [95% CI, 0.28, 0.97]; p=0.04; I=0%) but not symptomatic deep vein thrombosis (risk ratio, 0.86 [95% CI, 0.59, 1.25]; p=0.43). Major bleeding (risk ratio, 0.82 [95% CI, 0.56, 1.21]; p=0.32; I=50%) and mortality (risk ratio, 0.89 [95% CI, 0.78, 1.02]; p=0.09; I=0%) rates were similar. Compared with unfractionated heparin, low-molecular-weight heparin reduced rates of pulmonary embolism (risk ratio, 0.62 [95% CI, 0.39, 1.00]; p=0.05; I=53%) and symptomatic pulmonary embolism (risk ratio, 0.58 [95% CI, 0.34, 0.97]; p=0.04) but not deep vein thrombosis (risk ratio, 0.90 [95% CI, 0.74, 1.08]; p=0.26; I=0%), symptomatic deep vein thrombosis (risk ratio, 0.87 [95% CI, 0.60, 1.25]; p=0.44; I=0%), major bleeding (risk ratio, 0.97 [95% CI, 0.75, 1.26]; p=0.83; I=0%), or mortality (risk ratio, 0.93 [95% CI, 0.82, 1.04]; p=0.20; I=31%). CONCLUSIONS: Trial evidence to date suggests that any type of heparin thromboprophylaxis decreases deep vein thrombosis and pulmonary embolism in medical-surgical critically ill patients, and low-molecular-weight heparin compared with bid unfractionated heparin decreases pulmonary embolism and symptomatic pulmonary embolism. Major bleeding and mortality rates do not appear to be significantly influenced by heparin thromboprophylaxis in the ICU setting. Trial methodology, indirectness, and the heterogeneity and imprecision of some results temper inferences from this literature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The incidence of DVT acquired in the ICU may be as high as 10% [497], the incidence of acquired PE may be 2–4% [498, 499].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [498]
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
Mismetti, P., Laporte, S., Darmon, J.-Y., Buchmüller, A., & Decousus, H. (2001) · Journal of British Surgery · doi:10.1046/j.0007-1323.2001.01800.x · Cited by 649 · cited 4×
“These results complement estimates from trials in general medical patients (1, 2) and surgical populations (3, 42) yielding similar findings.”
BackgroundResultInfluentialDeep Vein Thrombosis and Its Prevention in Critically Ill Adults
Attia, J., Ray, J. G., Cook, D. J., Douketis, J., Ginsberg, J. S., & Geerts, W. H. (2001) · Archives of Internal Medicine · doi:10.1001/archinte.161.10.1268 · Cited by 617 · cited 9×
“If the natural history of VTE in critically ill patients parallels that in other patients, the prevalence of PE in this review is likely to be conservative, because trial patients in whom DVT might develop are typically therapeutically anticoagulated, thereby lowering the risk of thrombus propagation, embolization, an…”
BackgroundInfluentialSelf-citationInterstitial Lung Disease: A Quantitative Study Using the Adaptive Multiple Feature Method
UPPALURI, R., HOFFMAN, E. A., SONKA, M., HUNNINGHAKE, G. W., & McLENNAN, G. (1999) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.159.2.9707145 · Cited by 564
Dentali, F., Douketis, J. D., Gianni, M., Lim, W., & Crowther, M. A. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-4-200702200-00007 · Cited by 544 · cited 4×
“These results complement estimates from trials in general medical patients (1, 2) and surgical populations (3, 42) yielding similar findings.”
BackgroundResultInfluentialSelf-citation(2009) · The Lancet · doi:10.1016/s0140-6736(09)60941-7 · Cited by 481 · cited 1×
“However, the effect of antiembolic stockings has been called into question by the Clots in Legs Or sTockings after Stroke (CLOTS)-1 (40) and CLOTS-2 (41) trials, and pneumatic compression devices have not been tested in trials in this population.”
BackgroundDalteparin versus Unfractionated Heparin in Critically Ill Patients
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014475 · Cited by 459
Pogue, J. M., & Yusuf, S. (1997) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00051-2 · Cited by 415 · cited 1×
“parisons exceeds the threshold of the optimal information size (39), we conservatively downgraded the quality of evidence for some endpoints with very few events due to imprecision.”
BackgroundPrevalence of Deep Venous Thrombosis Among Patients in Medical Intensive Care
Hirsch, D. R. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03530040063042 · Cited by 318 · cited 3×
“Symptomatic DVT 2 (4,722) Intervention, 51/2,351 (2.”
Background
Research works printed but not linked: 1
- Goldhaber, 2000, J Am Coll Cardiol, 35, 325A
Cited by
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
“incidence of acquired PE may be 2%–4% (513, 514).”
BackgroundSelf-citationSurviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Self-citationSurviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Self-citationSurviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Self-citationRossaint, R., Bouillon, B., Cerny, V., Coats, T. J., Duranteau, J., Fernández-Mondéjar, E., Filipescu, D., Hunt, B. J., Komadina, R., Nardi, G., et al. (2016) · Critical Care · doi:10.1186/s13054-016-1265-x · Cited by 1,484
“A systematic review and meta-analysis [664] showed that any type of heparin thromboprophylaxis decreases”
BackgroundSpahn, D. R., Bouillon, B., Cerny, V., Duranteau, J., Filipescu, D., Hunt, B. J., Komadina, R., Maegele, M., Nardi, G., Riddez, L., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2347-3 · Cited by 1,269
“A systematic review and meta-analysis [851] showed that any type of heparin thromboprophylaxis decreases DVT and PE in critically ill medical and surgical patients, and low molecular weight heparin (LMWH) compared with twice daily unfractionated heparin (UFH) decreases both the overall rate and symptomatic rate of PE.”
BackgroundRossaint, R., Afshari, A., Bouillon, B., Cerny, V., Cimpoesu, D., Curry, N., Duranteau, J., Filipescu, D., Grottke, O., Grønlykke, L., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04327-7 · Cited by 776
Schünemann, H. J., Cushman, M., Burnett, A. E., Kahn, S. R., Beyer-Westendorf, J., Spencer, F. A., Rezende, S. M., Zakai, N. A., Bauer, K. A., Dentali, F., et al. (2018) · Blood Advances · doi:10.1182/bloodadvances.2018022954 · Cited by 819
“We identified 1 systematic review that addressed this question in critically ill medical patients.(114) Three RCTs in this review fulfilled the inclusion criteria and measured relevant outcomes (eg, mortality, PE, DVT, major bleeding, and thrombocytopenia).”
BackgroundPrevention, Diagnosis, and Treatment of VTE in Patients With Coronavirus Disease 2019
Moores, L. K., Tritschler, T., Brosnahan, S., Carrier, M., Collen, J. F., Doerschug, K., Holley, A. B., Jimenez, D., Le Gal, G., Rali, P., et al. (2020) · Chest · doi:10.1016/j.chest.2020.05.559 · Cited by 638
Bhaskar, S., Sinha, A., Banach, M., Mittoo, S., Weissert, R., Kass, J. S., Rajagopal, S., Pai, A. R., & Kutty, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01648 · Cited by 511
“The guidelines recommend consideration of LMWH in all patients requiring hospital admission for COVID-19 except those in whom anticoagulation is contraindicated (71).”
BackgroundAlhazzani, W., Evans, L., Alshamsi, F., Møller, M. H., Ostermann, M., Prescott, H. C., Arabi, Y. M., Loeb, M., Ng Gong, M., Fan, E., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000004899 · Cited by 417
“A meta-analysis of three RCTs (n = 5188) found that LMWH probably reduces VTE without increasing the risk of bleeding (51).”
BackgroundSelf-citationVenous thromboembolism in the ICU: main characteristics, diagnosis and thromboprophylaxis
Minet, C., Potton, L., Bonadona, A., Hamidfar-Roy, R., Somohano, C. A., Lugosi, M., Cartier, J.-C., Ferretti, G., Schwebel, C., & Timsit, J.-F. (2015) · Critical Care · doi:10.1186/s13054-015-1003-9 · Cited by 270
“A recent review described a significant reduction in PE, but not DVT, with LMWH compared with UFH, with a similar rate of bleeding [63].”
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Journal of Intensive Care · doi:10.1186/s40560-021-00555-7 · Cited by 224
Adjunctive intermittent pneumatic compression for venous thromboprophylaxis.
Arabi, Y. M., Al-Hameed, F., Burns, K. E. A., Mehta, S., Alsolamy, S. J., Alshahrani, M. S., Mandourah, Y., Almekhlafi, G. A., Almaani, M., Al Bshabshe, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816150 · Cited by 215
Obi, A. T., Pannucci, C. J., Nackashi, A., Abdullah, N., Alvarez, R., Bahl, V., Wakefield, T. W., & Henke, P. K. (2015) · JAMA Surgery · doi:10.1001/jamasurg.2015.1841 · Cited by 186
Natural Products Containing a Nitrogen–Sulfur Bond
Petkowski, J. J., Bains, W., & Seager, S. (2018) · Journal of Natural Products · doi:10.1021/acs.jnatprod.7b00921 · Cited by 180
Associations Between Ventilator Bundle Components and Outcomes
Klompas, M., Li, L., Kleinman, K., Szumita, P. M., & Massaro, A. F. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.2427 · Cited by 170
Wang, C., Chi, C., Guo, L., Wang, X., Guo, L., Sun, J., Sun, B., Liu, S., Chang, X., & Li, E. (2014) · Critical Care · doi:10.1186/s13054-014-0563-4 · Cited by 129
“A meta-analysis of heparin therapy in medically critical surgical patients [31] revealed that heparin can effectively prevent deep vein thrombosis (DVT) without increasing the risk of bleeding.”
BackgroundS3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge
Deutsche Sepsis Gesellschaft e., V., Brunkhorst, F. M., Weigand, M. A., Pletz, M. W., Gastmeier, P., Lemmen, S., Meier‐Hellmann, A., Ragaller, M., Weyland, A., Marx, G., et al. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00685-0 · Cited by 150
Seminario‐Vidal, L., Kroshinsky, D., Malachowski, S. J., Sun, J. X., Markova, A., Beachkofsky, T. M., Kaffenberger, B. H., Ergen, E. N., Mauskar, M., Bridges, A. G., et al. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.02.066 · Cited by 124
European guidelines on perioperative venous thromboembolism prophylaxis: Intensive care
Duranteau, J., Taccone, F. S., Verhamme, P. B., & Ageno, W. (2017) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000000707 · Cited by 123
Egi, M., Ogura, H., Yatabe, T., Atagi, K., Inoue, S., Iba, T., Kakihana, Y., Kawasaki, T., Kushimoto, S., Kuroda, Y., et al. (2021) · Acute Medicine & Surgery · doi:10.1002/ams2.659 · Cited by 96
Venous Thromboembolism Prophylaxis in Critically Ill Patients
Boonyawat, K., & Crowther, M. A. (2015) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0034-1398386 · Cited by 92
“14 A large observational study using data from International Medical Prevention Registry on Venous Thrombo-embolism (IMPROVE) assessed in-hospital bleeding risk in acutely ill medical patients.”
MethodDeep Vein Thrombosis in Intensive Care
Boddi, M., & Peris, A. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_114 · Cited by 75
A Multinational Study of Thromboprophylaxis Practice in Critically Ill Children*
Faustino, E. V. S., Hanson, S. J., Spinella, P. C., Tucci, M., O’Brien, S. H., Rodríguez‐Núñez, A., Yung, M., Truemper, E. J., Li, Q., Li, S., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0000000000000147 · Cited by 80
“Critically ill adults with no contraindication to anticoagulation are strongly recommended to receive pTP based on strong evidence that pTP decreases the prevalence of DVT and PE in this population (2).”
BackgroundBeitland, S., Sandven, I., Kjærvik, L.-K., Sandset, P. M., Sunde, K., & Eken, T. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3840-z · Cited by 68
“However, systematic reviews of the recent medical knowledge seem to be lacking in general ICU patients, even though it has been performed for various subgroups of ICU patients [6, 9].”
BackgroundSinger, M., Angus, D., Annane, D., Bauer, M. W., Kalil, A. C., Klompas, M., Machado, F. R., Martin, G. S., Randolph, A. G., Shankar‐Hari, M., et al. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02422-5 · Cited by 83
Management of the thrombotic risk associated with COVID-19: guidance for the hemostasis laboratory
Hardy, M. J., Lecompte, T., Douxfils, J., Lessire, S., Dogné, J., Châtelain, B., Testa, S., Gouin‐Thibault, I., Gruel, Y., Medcalf, R. L., et al. (2020) · Thrombosis Journal · doi:10.1186/s12959-020-00230-1 · Cited by 73
The Prophylaxis of Venous Thromboembolism
Encke, A., Haas, S. K., & Kopp, I. (2016) · Deutsches Ärzteblatt international · doi:10.3238/arztebl.2016.0532 · Cited by 75
Thromboprophylaxis in Intensive Care Unit Patients: A Literature Review
Ejaz, A., Ahmed, M. M., Tasleem, A., Niazi, M. R. K., Ahsraf, M. F., Ahmad, I., Zakir, A., & Raza, A. (2018) · Cureus · doi:10.7759/cureus.3341 · Cited by 55
“However, on comparing UFH and LMWH, the efficacy was found to be comparable, which was also in agreement with the previous analysis [32-33].”
Venous Thromboembolism in Hospitalized Adolescents: An Approach to Risk Assessment and Prophylaxis
Meier, K. A., Clark, E., Tarango, C., Chima, R. S., & Shaughnessy, E. E. (2015) · Hospital Pediatrics · doi:10.1542/hpeds.2014-0044 · Cited by 53
Pannucci, C. J., Andrea, T., Alvarez, R., Abdullah, N. M., Nackashi, A., Hu, H. M., Bahl, V., & Henke, P. K. (2014) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2014.01.046 · Cited by 46
Sarkar, M. S., Madabhavi, I., Quy, P. N., & Govindagoudar, M. B. (2021) · The Clinical Respiratory Journal · doi:10.1111/crj.13438 · Cited by 47
“Alhazzani et al.(83) in a systematic review and metaanalysis that included seven trials with 7226 medicalsurgical ICU patients in 2013 observed that compared with UFH, LMWH reduced the rates of pulmonary TAB L E 2 The International Society of Thrombosis and Haemostasis (ISTH) proposed “sepsis-induced coagulopathy” (SI…”
ResultInfluentialКirov, М. Y., Владимирович, К. В., Николаевич, П. Д., Щеголев, А. В., Babaev, M. A., Belotserkovskiy, B. Z., Bykov, A. O., Gritsan, A. I., Кулабухов, В. В., Kulikov, A. V., et al. (2023) · Annals of critical care · doi:10.21320/1818-474x-2023-4-7-42 · Cited by 44
Park, J., Lee, J. M., Lee, J. S., & Cho, Y. (2016) · Journal of Korean Medical Science · doi:10.3346/jkms.2016.31.11.1828 · Cited by 38
“(5) reported that thromboprophylaxis with any type of heparin reduced the rates of DVT to half (pooled risk ratio, 0.”
BackgroundWang, L., Li, H., Gu, X., Wang, Z., Liu, S., & Chen, L. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154754 · Cited by 33
Sauro, K. M., Bagshaw, S. M., Niven, D. J., Soo, A., Brundin‐Mather, R., Leigh, J. P., Cook, D. J., & Stelfox, H. T. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-024159 · Cited by 36
Self-citationLópes, R. D., & Fanaroff, A. C. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.09.008 · Cited by 33
“Multiple randomized controlled trials have demonstrated that prophylactic anticoagulation reduces pulmonary embolism in hospitalized medically ill patients, with a stronger effect on critically ill patients (9,10); current guideline recommendations reflect these data (11).”
BackgroundThromboprophylaxis patterns and determinants in critically ill patients: a multicenter audit
Lauzier, F., Muscedere, J., Deland, É., Kutsogiannis, D. J., Jacka, M. J., Heels‐Ansdell, D., Crowther, M. A., Cartin‐Ceba, R., Cox, M. J., Zytaruk, N. L., et al. (2014) · Critical Care · doi:10.1186/cc13844 · Cited by 37
Self-citationLi, G., Cook, D. J., Levine, M., Guyatt, G. H., Crowther, M. A., Heels‐Ansdell, D., Holbrook, A. M., Lamontagne, F., Walter, S. D., Ferguson, N. D., et al. (2015) · Medicine · doi:10.1097/md.0000000000001479 · Cited by 31
Self-citationDeutsche Sepsis Gesellschaft e., V., Brunkhorst, F. M., Weigand, M. A., Pletz, M. W., Gastmeier, P., Lemmen, S., Meier‐Hellmann, A., Ragaller, M., Weyland, A., Marx, G., et al. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00671-6 · Cited by 37
Taccone, F. S., Bunker, N., Waldmann, C. S., Backer, D. D., Brohi, K., Jones, R. G., & Vincent, J. (2015) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000000756 · Cited by 31
Factor VIII May Predict Catheter-Related Thrombosis in Critically Ill Children: A Preliminary Study*
Faustino, E. V. S., Li, S., Silva, C. T., Pinto, M. G., Li, Q., Tala, J. A., Rinder, H. M., Kupfer, G. M., & Shapiro, E. D. (2015) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000000409 · Cited by 31
“Although routinely used in critically ill adults, pharmacologic thromboprophylaxis is not recommended in children with CVC due to paucity of studies to support this practice (3, 4).”
BackgroundEpidemiology of Lower Extremity Deep Venous Thrombosis in Critically Ill Adolescents
Faustino, E. V. S., Shabanova, V., Pinto, M. G., Li, S., Trakas, E., Miksa, M., Gertz, S., Polikoff, L. A., Napolitano, M., Brudnicki, A. R., et al. (2018) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.05.006 · Cited by 32
Eck, R. J., Bult, W., Wetterslev, J., Gans, R. O. B., Meijer, K., van der Horst, I. C. C., & Keus, F. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8122039 · Cited by 29
Pellegrini, J. A. S., Rech, T. H., Schwarz, P., Tonelli, A. C., Vieceli, T., Moraes, R. B., Sekine, L., & Viana, M. V. (2021) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-021-02395-6 · Cited by 28
Pelland‐Marcotte, M., Amiri, N., Avila, L., & Brandão, L. R. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005982.pub3 · Cited by 29
Brandão, L. R., Shah, N. C., & Shah, P. S. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005982.pub2 · Cited by 29
Stelfox, H. T., Brundin‐Mather, R., Soo, A., Leigh, J. P., Niven, D. J., Fiest, K. M., Doig, C. J., Zuege, D. J., Kushner, B., Clement, F. M., et al. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05532-1 · Cited by 28
Self-citationVenous thromboembolism in critically ill children
Polikoff, L. A., & Faustino, E. V. S. (2014) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000084 · Cited by 27
“In critically ill adults, pharmacologic thromboprophylaxis is highly recommended because of its proven efficacy and safety in preventing DVT and its complications [39].”
BackgroundWho Cares about Preventing Acute Respiratory Distress Syndrome?
Rubenfeld, G. D. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201408-1574cp · Cited by 27
Gomez, K., Laffan, M., & Bradbury, C. A. (2020) · British Journal of Haematology · doi:10.1111/bjh.17241 · Cited by 26
“found no difference in the risk of major bleeding between heparin prophylaxis and placebo.(16) Historical data suggest a moderate or severe bleeding rate of 3 5% in patients receiving therapeutic heparin in hospital.”
BackgroundVenous Thromboembolism in Critical Illness and Trauma: Pediatric Perspectives
Chima, R. S., & Hanson, S. J. (2017) · Frontiers in Pediatrics · doi:10.3389/fped.2017.00047 · Cited by 24
Prevention and Management of Venous Thromboembolism
Paul, J., & Cifu, A. S. (2019) · JAMA · doi:10.1001/jama.2019.13853 · Cited by 24
Challenging management dogma where evidence is non-existent, weak or outdated
Hofmaenner, D. A., & Singer, M. (2022) · Intensive Care Medicine · doi:10.1007/s00134-022-06659-4 · Cited by 23
“Yet, how strong is the evidence that thromboprophylaxis actually makes a difference in this patient population? In a 2013 meta-analysis, Alhazzani and colleagues could only identify three studies published between 1982 and 2000 comparing either unfractionated (UFH) or low molecular weight (LMWH) heparin prophylaxis ag…”
BackgroundCook, D., Duffett, M., Lauzier, F., Ye, C., Dodek, P., Paunovic, B. N., Fowler, R. A., Kho, M. E., Foster, D., Stelfox, H. T., et al. (2014) · Journal of Critical Care · doi:10.1016/j.jcrc.2014.01.017 · Cited by 23
Self-citationSauro, K. M., Soo, A., Kramer, A. H., Couillard, P. L., Kromm, J. A., Zygun, D. A., Niven, D. J., Bagshaw, S. M., & Stelfox, H. T. (2018) · Neurocritical Care · doi:10.1007/s12028-018-0614-9 · Cited by 23
Resuscitation and intensive care in acute massive blood loss in adults (clinical guidelines)
Grigoryev, E. V., Лебединский, К. М., Schegolev, А. V., Bobovnik, S. V., Bulanov, А. Y., Zabolotskikh, I. B., Sinkov, S. V., Shen, N. P., & KORNELYUK, R. A. (2020) · Russian Journal of Anesthesiology and Reanimatology · doi:10.17116/anaesthesiology20200115 · Cited by 27
Li, L., Zhou, J., Huang, L., Zhen, J., Yao, L., Xu, L., Zhang, W., Zhang, G., Chen, Q., Cheng, B., et al. (2021) · Annals of Medicine · doi:10.1080/07853890.2021.2005822 · Cited by 25
“Recent meta-analyses showed that mechanical prophylaxis is effective but there is a risk of pressure injury [33,36,37].”
BackgroundKim, N. Y., Ryu, S., & Kim, Y.-H. (2024) · PLoS ONE · doi:10.1371/journal.pone.0307602 · Cited by 22
PROF-ETEV study: prophylaxis of venous thromboembolic disease in critical care units in Spain
García-Olivares, P., Guerrero, J. E., Galdós, P., Carriedo, D., Murillo, F., & Rivera, A. M. C. (2014) · Intensive Care Medicine · doi:10.1007/s00134-014-3442-1 · Cited by 22
“52) [25] and a prospective cohort study (HR 0.”
BackgroundLenka, J., Chhabria, M., Sharma, N., Tan, B. E., Boppana, L. K. T., Venugopal, S., & Sondhi, D. (2020) · Journal of Community Hospital Internal Medicine Perspectives · doi:10.1080/20009666.2020.1811070 · Cited by 23
“The increased risk in thrombotic complications with COVID-19 is difficult to ascertain especially in critically ill patients where risk of clotting is ~20%[24].”
BackgroundCOVID-19 Thrombotic Complications and Therapeutic Strategies
Fanaroff, A. C., & Lópes, R. D. (2022) · Annual Review of Medicine · doi:10.1146/annurev-med-042921-110257 · Cited by 22
Al-Hameed, F. M., Al‐Dorzi, H. M., Abdelaal, M., Alaklabi, A. A., Bakhsh, E., Alomi, Y. A., Baik, M. A., Aldahan, S., Schünemann, H. J., Brożek, J., et al. (2016) · Saudi Medical Journal · doi:10.15537/smj.2016.11.15268 · Cited by 23
Mer, M., Schultz, M. J., & Adhikari, N. K. J. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4831-z · Cited by 22
Bachler, M., Hell, T., Bösch, J., Treml, B., Schenk, B., Treichl, B., Friesenecker, B. E., Lorenz, I. H., Stengg, D., Hruby, S., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9040963 · Cited by 20
Gratz, J., Oberladstätter, D., & Schöchl, H. (2020) · Hämostaseologie · doi:10.1055/a-1232-7721 · Cited by 20
Vahtera, A., Vaara, S. T., Pettilä, V., & Kuitunen, A. H. (2016) · Thrombosis Research · doi:10.1016/j.thromres.2015.12.016 · Cited by 21
“Because of the lack of good quality RCTs [35], evidence of the effectiveness of LMWH thromboprophylaxis in ICU patients is mainly based on measurements of plasma levels of anti-FXa, as anti-FXa is a surrogate marker for anticoagulant effects.”
BackgroundInfluentialFontaine, G., Vigil, E., Wohlt, P. D., Lloyd, J. F., Evans, R. S., Collingridge, D. S., Stevens, S. M., & Woller, S. C. (2015) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029615604048 · Cited by 22
“Current guidelines recommend critically ill patients receive either LMWH or UFH (Grade 2C), and although some evidence supports considering dose adjustments for VTE prophylaxis among the obese,(31) little guidance exists.(30) In nonorthopedic surgical patients, guidelines suggest consulting with a pharmacist for dosin…”
BackgroundSchmitt, F. C. F., Schöchl, H., Brün, K., Kreuer, S., Schneider, S. O., Hofer, S., & Weber, C. F. (2024) · Die Anaesthesiologie · doi:10.1007/s00101-023-01368-z · Cited by 17
“Eine frühe medi-kamentöse TE-Prophylaxe kann zu einer signifikanten Reduktion der Inzidenz tiefer Venenthrombosen (TVT) und von LE bei intensivmedizinischen und chirurgischen Patienten beitragen [114].”
BackgroundChloroquine and Hydroxychloroquine
Barber, B. E. (2017) · doi:10.1201/9781498747967-175 · Cited by 15
Thromboprophylaxis with argatroban in critically ill patients with sepsis: a review
Bachler, M., Asmis, L. M., Koscielny, J., Lang, T., Nowak, H., Paulus, P., Schewe, J., von Heymann, C., & Fries, D. R. (2022) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0000000000001133 · Cited by 15
Retrospective Evaluation of Venous Thromboembolism Prophylaxis in Elderly, High-Risk Trauma Patients
Krantz, E., Philpott, C. D., Droege, M. E., Mueller, E. W., Ernst, N. E., Garber, P. M., Tsuei, B. J., Goodman, M. D., & Droege, C. A. (2020) · Journal of Surgical Research · doi:10.1016/j.jss.2019.12.024 · Cited by 14
Incidence of proximal deep vein thrombosis in medical critical care patients
Permpikul, C., Chaiyasoot, W., & Panitchote, A. (2022) · Thrombosis Journal · doi:10.1186/s12959-022-00363-5 · Cited by 13
“[4], while adjunctive treatment with intermittent pneumatic compression did not have additional benefits in proximal lower limb DVT prevention [5].”
BackgroundSamuel, S., Li, W., Dunn, K. M., Cortes, J. E., Nguyen, T., Moussa, D., Kumar, A., Dao, T., Beeson, J. G., Choi, H. A., et al. (2023) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-023-02795-w · Cited by 12
“LMWH showed reductions in pulmonary embolism (PE), symptomatic deep vein thrombosis (DVT), but estimates were imprecise, with very small benefits [6].”
BackgroundSulaiman, K. A. A., Aljuhani, O. A., Korayem, G. B., Hafiz, A. M., Alalawi, M., Badreldin, H. A., Altebainawi, A. F., Vishwakarma, R. K., Alissa, A. S., Alghamdi, A., et al. (2022) · Thrombosis Journal · doi:10.1186/s12959-022-00432-9 · Cited by 13
Efficacy and safety profiles of mechanical and pharmacological thromboprophylaxis
Ganau, M., Ligarotti, G. K. I., Meloni, M., & Chibbaro, S. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.08.44 · Cited by 12
Excellence of the closed intensive care unit system in critically ill surgical patients
Baik, S. M., Yang, N. R., Kim, T. Y., & Hong, K. S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0285035 · Cited by 11
Klingele, M., Enkel, J., Speer, T., Bomberg, H., Baerens, L., & Schäfers, H. (2020) · Journal of Cardiothoracic Surgery · doi:10.1186/s13019-020-1059-8 · Cited by 11
Mechanical Ventilation and Hospital-Acquired Venous Thromboembolism Among Critically Ill Children
Sochet, A. A., Havlicek, E., Faustino, E. V. S., & Goldenberg, N. A. (2022) · Hospital Pediatrics · doi:10.1542/hpeds.2022-006697 · Cited by 11
Critical Care in the Severely Burned
Culnan, D. M., Sherman, W. C., Chung, K. K., & Wolf, S. E. (2018) · Elsevier eBooks · doi:10.1016/b978-0-323-47661-4.00032-0 · Cited by 11
Wills, N. K., Nair, N., Patel, K., Sikder, O., Adriaanse, M., Eikelboom, J. W., & Wasserman, S. A. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac285 · Cited by 10
Major publications in the critical care pharmacotherapy literature: January–December 2013
Rech, M. A., Day, S. A., Kast, J. M., Donahey, E. E., Pajoumand, M., Kram, S. J., Erdman, M. J., Peitz, G. J., Allen, J. M., Palmer, A. E., et al. (2015) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp140241 · Cited by 10
Bertoletti, L., Murgier, M., & Stelfox, H. T. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05605-1 · Cited by 10
Prayag, S., Govil, D., Pandit, R. A., Zirpe, K. G., Dixit, S., Mishra, R. C., Chanchalani, G., Kapadia, F. N., Chhallani, A. A., Jagiasi, B. G., et al. (2022) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-24195 · Cited by 9
Amin, A., Kartashov, A. I., Ngai, W., Steele, K., & Rosenthal, N. A. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1163684 · Cited by 9
Schryver, N. D., Serck, N., Eeckhoudt, S., Laterre, P., Wittebole, X., & Gérard, L. (2022) · Journal of Critical Care · doi:10.1016/j.jcrc.2022.154029 · Cited by 8
Tang, X., Lyu, W., Jin, Y., Wang, R., Li, X., Li, Y., Zhang, C., Zhao, W., Tong, Z.-H., & Sun, B. (2022) · Thrombosis Journal · doi:10.1186/s12959-022-00439-2 · Cited by 8
European guidelines on peri-operative venous thromboembolism prophylaxis: first update.
Bounes, F. V., Ferrandis, R., Frère, C., Helms, J., & Llau, J. V. (2024) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000002011 · Cited by 8
Thromboprophylaxis in critically ill patients: balancing on a tightrope
Schizodimos, T., Soulountsi, V., Iasonidou, C., & Kapravelos, N. (2021) · Minerva Anestesiologica · doi:10.23736/s0375-9393.21.15755-4 · Cited by 8
Thrombo-prophylaxis in acutely ill medical and critically ill patients
Joshi, R. P., Saigal, S., Sharma, J. P., & Singh, D. (2014) · Indian Journal of Critical Care Medicine · doi:10.4103/0972-5229.133902 · Cited by 9
“As compared to placebo patients had similar bleeding rates, mortality, and symptomatic DVT.[7] (ii) Compared with UFH, LMWH reduced rates of PE (RR, 0.62 [95% CI, 0.39, 1.00]; P = 0.05; I2 = 53”
MethodResultInfluentialEpidemiology of Clinically Relevant Bleeding in Critically Ill Adolescents*
Pinto, M. G., Shabanova, V., Li, S., Trakas, E. V., Miksa, M., Gertz, S. J., Polikoff, L. A., Tala, J. A., & Faustino, E. V. S. (2019) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000002018 · Cited by 8
Wang, M., Wang, W., Xue, J., He, Q., Zhu, S., Kang, Y. M., Zhang, R., Ren, Y. D., Li, L., Zou, K., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.891178 · Cited by 7
“Two systematic review and meta-analyses showed significantly lower risk of DVT and PE in patients receiving thromboprophylaxis than those without (Alhazzani et al., 2013; Park et al., 2016).”
BackgroundThromboprophylaxis Failure in the Adult Medical Inpatient
Northup, A., & Wilcox, S. R. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2017.03.011 · Cited by 7
Preventing Venous Thromboembolism in Adults
(2016) · Critical Care Nurse · doi:10.4037/ccn2016638 · Cited by 7
Seshadri, M., Ahamed, J., & Laurence, J. C. (2020) · Thrombosis Update · doi:10.1016/j.tru.2020.100009 · Cited by 7
The Use of Bayesian Analysis Techniques in Pediatric Research
Anderson, M. P., & Cooper, M. T. (2019) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2018.11.059 · Cited by 6
Does intermittent pneumatic compression PREVENT deep vein thrombosis in the ICU?
Laupland, K. B., Tabah, A., Kelway, C., & Lipman, J. (2019) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2019.05.006 · Cited by 6
“Accordingly, barring contraindications or indications for therapeutic anticoagulation otherwise, all patients admitted to ICU are recommended to receive this therapy (3).”
BackgroundImpact of Obesity on Tranexamic Acid Efficacy in Adult Patients With Major Bleeding
Franz, N. D., Machado-Aranda, D., Miller, J. T., & Farina, N. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020983323 · Cited by 5
Inflammatory pathways and potential therapies for COVID-19: A mini review
Dabbish, A. M., Yonis, N., Salama, M., Essa, M. M., & Qoronfleh, M. W. (2021) · European Journal of Inflammation · doi:10.1177/20587392211002986 · Cited by 6
Metadata
- Authors
- Alhazzani, W., Lim, W., Jaeschke, R. Z., Murad, M. H., Cade, J., & Cook, D. J.
- Affiliations
- McMaster University (CA)
- Mayo Clinic (US)
- The Royal Melbourne Hospital (AU)
- Venue
- Critical Care Medicine
- Published
- 2013-09
- Volume
- 41
- Issue
- 9
- Pages
- 2088-2098
- ISSN
- 0090-3493 (ISSN-L)
- OpenAlex
- W2321905524
- Semantic Scholar
- f75126a5fd7772a2752c0acc656c0010d7a06dc7
- Cited by
- 168
- References
- 29
- Citations by year
- 2026: 9 · 2025: 3 · 2024: 10 · 2023: 11 · 2022: 19 · 2021: 15 · 2020: 23 · 2019: 19 · 2018: 8 · 2017: 9 · 2016: 10 · 2015: 13 · 2014: 16 · 2013: 3
- FWCI
- 12.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Critical Care Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Canadian Institutes of Health Research
- Topics
- Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
- Keywords
- thromboprophylaxis, deep vein thrombosis, pulmonary embolism, low molecular weight heparin, unfractionated heparin, major bleeding, mortality, intensive care unit patients, symptomatic pulmonary embolism, quality metrics, risk of bias
- MeSH terms
- Anticoagulants, Heparin, Low-Molecular-Weight, Hospitalization, Humans, Intensive Care Units, Randomized Controlled Trials as Topic, Critical Illness, Treatment Outcome, Venous Thrombosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.